{
    "nct_id": "NCT04235257",
    "official_title": "Immunogenicity of Fractional Dose of the Bivalent and Nonavalent Intradermal HPV Vaccines.",
    "inclusion_criteria": "* Age 27-45 years at enrollment\n* Not intending to receive the HPV vaccine series for the duration of the study participation\n* Willing and able to provide written informed consent, undergo clinical evaluation, and adhere to follow-up schedule\nHealthy volunteers allowed\nMust have minimum age of 27 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "* Prior immunization with HPV-vaccine (Cervarix, Gardasil-4, Gardasil-9)\n* Currently pregnant or breastfeeding\n* Immune deficiency or other immune disorder\n* HIV infection or continued high risk for HIV; patients at risk for HIV who do not have a negative HIV test in the last 6 months will be excluded\n* Cancer or chemotherapy (current, within 6 months, or anticipated in the future) except for fully excised non-melanoma skin cancer)\n* Unstable medical condition (e.g., malignant hypertension, poorly controlled diabetes,\n* Known allergy to vaccine components\n* Prior history of HPV-associated cancer",
    "miscellaneous_criteria": ""
}